ClinicalTrials.gg
CompletedNCT02428712Updated Jul 29, 2025

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

A Phase 1/2 interventional study of FORE8394 in Advanced Unresectable Solid Tumors and BRAF-mutated Tumors, sponsored by Fore Biotherapeutics. Completed at 13 sites in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Fore Biotherapeutics · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Study summary

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.

Read the detailed description

Dose Escalation (Part 1): To evaluate safety, pharmacokinetics, pharmacodynamics of FORE8394 in adult and pediatric patients with advanced BRAF- mutated tumors, and to identify the recommended Phase 2 Dose.

Dose Extension (Part 2): To access objective tumor response to FORE8394 treatment in adult and in adolescent patients with advanced BRAF- mutated tumors, to access RECIST, and to access pharmacokinetics, pharmacodynamics, and safety.

02

Conditions studied

  • Advanced Unresectable Solid Tumors
  • BRAF-mutated Tumors
03

In context

Lead sponsor

Fore Biotherapeutics is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 10 years and at least 30 kg.
  • Phase 1-Dose Escalation (no longer enrolling as of Protocol Amendment 10): Patients with confirmed advanced solid tumors who are to, relapsed after, or intolerant to standard therapy or for whom no standard therapy exists.
  • Phase 2a-Dose Extension: Criteria for Dose Extension [HME] Cohort 1 or Cohort 2, are specified below:

    • Phase 2a-Dose Extension-Cohort 1

      1. Patients with solid tumors (as of Amendment 10, only subjects with glioma tumors) driven by an activating BRAF-V600 mutation
      2. Patients with no prior exposure to BRAF-directed therapy and for whom no standard therapy exists.
    • Phase 2a-Dose Extension-Cohort 2

      1. Patients with solid tumors driven by an activating BRAF non-V600 mutation, which can include a point mutation, gene amplification, fusion, insertion, or deletion
      2. Participants with no prior exposure to BRAF-directed therapy and for whom no standard therapy exists.
  • Phase 2a - RP2D Redefinition Extension: Following RP2D redefinition, extension participants must meet criteria for Cohort 3 or Cohort 4 as specified below:

    1. Cohort 3: Participants with advanced unresectable gliomas driven by an activating BRAF V600 or activating non-V600 mutation who have no prior exposure to a BRAF, MEK, or ERK inhibitor and for whom no standard therapy exists.
    2. Cohorts 4-8: Participants with advanced solid tumors driven by activating BRAF non V600 mutations, which can include a point mutation, gene amplification, fusion, insertion, deletion, or alternative splicing, who have no prior exposure to a BRAF, MEK, or ERK inhibitor.
  • by 1.1.
  • RANOS (CNS tumors) - High Grade Glioma for high grade glioma (Grades 3 and 4) and RANO-Low Grade Glioma for low grade glioma.
  • (ECOG) performance status of 0-1.
  • Adequate hematologic, hepatic, and renal function.
  • Women of must have a negative pregnancy test and must agree to use an effective form of from the time of the negative pregnancy test up to 3 months after the last dose of study drug. Women of non-child-bearing potential may be included if they are either surgically sterile or have been for ≥ 1 year.
  • Fertile men must agree to use an effective method of birth control during the study and for up to 3 months after the last dose of study drug.
  • Completion of previous anti-cancer therapy at least 2 weeks before study drug initiation.

Exclusion criteria

Exclusion Criteria- Group A:

  • Participants with known co-occurring RAS-related mutations or RTK activation are not allowed.
  • Major surgical procedure, open (excluding skin cancer resection), or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study.
  • Uncontrolled intercurrent illness.
  • Patients with colorectal cancer or pancreatic cancer
  • Active secondary unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the Medical Monitor. Patients with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
  • nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption.
  • cardiac disease.
  • Known infection with , , or or a known carrier of HBV or HCV.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    FORE8394

    Group A: Phase 1-Dose Escalation: Adult patients. Group B: Phase 1-Dose Escalation: Pediatric patients. Phase 2a-Dose Extension: Adult patients with advanced unresectable solid tumors will be enrolled among two cohorts. * Cohort 1: Activating BRAF V600 mutations (glioma patients only) * Cohort 2: Activating BRAF non-V600 mutations Phase 2a-RP2D Confirmation: Adult patients. Phase 2a-RP2D Redefinition and Extension: * Cohort 3: Activating BRAF V600 or activating non-V600 mutation * Cohort 4: Activating BRAF non-V600 mutations Phase 2a-RP2D Redefinition: * Cohort 6A: Advanced activating BRAF-mutated solid tumors * Cohort 7A: Advanced activating BRAF-mutated solid tumors * Cohort 8A: Advanced activating BRAF-mutated solid tumors

    Drug: FORE8394

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  2. Maximum concentration (Cmax) of FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  3. Time to peak concentration (Tmax) of FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  4. Half life (T1/2) of FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  5. Number of participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v4.0.

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  6. To identify the recommended Phase 2 dose (RP2D) of FORE8394 in Group A (adult patients) for further evaluation in Dose Extension.

    Time frame: 2 years

  7. Compare AUC of FORE8394 with FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  8. Compare Cmax of FORE8394 with FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  9. Compare Tmax of FORE8394 with FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  10. Compare T1/2 of FORE8394 with FORE8394

    Time frame: First dose of FORE8394 up to 30 days after end of treatment

  11. To determine the overall response rate of FORE8394 treatment at the applicable RP2D in a) Group A, Cohort 1, and b) Group A, Cohort 2.

    Time frame: 5 years

Secondary outcomes

  1. To evaluate the duration of response (defined as time of initial response to progressive disease or death) at the applicable RP2D in Dose Extension.

    Time frame: 5 years

  2. To evaluate the progression free survival (defined as time of first dose to progressive disease or death) at the applicable RP2D in Dose Extension.

    Time frame: 5 years

  3. Clinical benefit rate (defined as stable disease, partial response and complete response) after 24 weeks on study

    Time frame: 5 years

07

Study locations

13 sites
  • HonorHealth
    Scottsdale, Arizona 85258, United States
  • St. Joseph's Hospital at Orange
    Orange, California 92868, United States
  • Stanford Hospitals and Clinics
    Stanford, California 94305, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Community Health Network
    Indianapolis, Indiana 46011, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Capital Regional Medical Center
    Jefferson City, Missouri 65101, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Children's Hospital (Baylor College of Medicine)
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jul 2024, 111 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2015
First posted
Apr 29, 2015
StartActual
Apr 2015
Primary completionActual
Jul 12, 2024
CompletionActual
Jul 12, 2024
Results delay requested
Jul 8, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02428712
Lead sponsor
Fore Biotherapeutics
Responsible party
Sponsor
First posted
Apr 29, 2015
Start date
Apr 2015
Primary completion
Jul 12, 2024
Completion
Jul 12, 2024
Last update
Jul 29, 2025

Study contacts

Stacie Peacock Shepherd, MD, PhD
study chair · Fore Biotherapeutics U.S. Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PLX8394

Start the discussion